Research programme: microbiome-based therapeutics - Genentech/Microbiotica

Drug Profile

Research programme: microbiome-based therapeutics - Genentech/Microbiotica

Alternative Names: Bacteriotherapies - Microbiotica

Latest Information Update: 11 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genentech; Microbiotica
  • Class Bacteria
  • Mechanism of Action Bacteria replacements; Microbiome modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Research Inflammatory bowel diseases

Most Recent Events

  • 06 Jun 2018 Microbiotica signs collaboration agreement with Genentech for development of microbiome-based therapeutics for Inflammatory bowel disease
  • 06 Jun 2018 Early research in Inflammatory bowel disease in USA (unspecified route)
  • 19 Dec 2016 Early research in Inflammatory bowel disease in United Kingdom (unspecified route) before December 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top